144 related articles for article (PubMed ID: 22487177)
1. Blocking HIV-1 entry by a gp120 surface binding inhibitor.
Tsou LK; Chen CH; Dutschman GE; Cheng YC; Hamilton AD
Bioorg Med Chem Lett; 2012 May; 22(9):3358-61. PubMed ID: 22487177
[TBL] [Abstract][Full Text] [Related]
2. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.
González-Ortega E; Mena MP; Permanyer M; Ballana E; Clotet B; Esté JA
Antimicrob Agents Chemother; 2010 Oct; 54(10):4487-92. PubMed ID: 20643898
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
Brower ET; Schön A; Freire E
Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
[TBL] [Abstract][Full Text] [Related]
6. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
Wang HG; Williams RE; Lin PF
Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
[TBL] [Abstract][Full Text] [Related]
7. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
8. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
[TBL] [Abstract][Full Text] [Related]
9. The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.
Fleta-Soriano E; Smutná K; Martínez JP; Lorca Oró C; Sadiq SK; Mirambeau G; Lopez-Iglesias C; Bosch M; Pol A; Brönstrup M; Diez J; Meyerhans A
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533249
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
Rivero-Buceta E; Doyagüez EG; Colomer I; Quesada E; Mathys L; Noppen S; Liekens S; Camarasa MJ; Pérez-Pérez MJ; Balzarini J; San-Félix A
Eur J Med Chem; 2015 Dec; 106():34-43. PubMed ID: 26513643
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the anti-HIV activity of papuamide A.
Andjelic CD; Planelles V; Barrows LR
Mar Drugs; 2008; 6(4):528-49. PubMed ID: 19172193
[TBL] [Abstract][Full Text] [Related]
12. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
13. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
14. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
15. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
16. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.
Parajuli B; Acharya K; Bach HC; Parajuli B; Zhang S; Smith AB; Abrams CF; Chaiken I
Biochem J; 2018 Mar; 475(5):931-957. PubMed ID: 29343613
[TBL] [Abstract][Full Text] [Related]
17. The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications.
Férir G; Petrova MI; Andrei G; Huskens D; Hoorelbeke B; Snoeck R; Vanderleyden J; Balzarini J; Bartoschek S; Brönstrup M; Süssmuth RD; Schols D
PLoS One; 2013; 8(5):e64010. PubMed ID: 23724015
[TBL] [Abstract][Full Text] [Related]
18. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
[TBL] [Abstract][Full Text] [Related]
19. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
20. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
